Purpose: A high‑yield, bedside‑ready summary of the most practice‑changing updates for emergency clinicians, based only on the 2025 AHA/ACC Multisociety Guideline.

---

1) Terminology & Triage

“Hypertensive Urgency” is OUT. Use Severe Hypertension for BP >180/120 mmHg without acute target organ damage (TOD).

ED approach:

• Do not chase the number in asymptomatic patients. Carefully screen for TOD (neuro, cardiac, renal, aortic, visual). If no TOD, start/restart/intensify orals, arrange rapid outpatient follow‑up, and provide home BP monitoring instructions.
• Harm alert (hospitalized non‑cardiac patients): avoid intermittent IV/PRN pulses of antihypertensives when there’s no acute TOD.

Actionable takeaways

• Admit only if TOD present (hypertensive emergency). Otherwise, outpatient pathway with meds + close follow‑up.
• Stage 2 HTN: Prefer single‑pill 2‑drug combinations to speed control and adherence.

---

2) Condition‑Specific Targets for Hypertensive Emergencies

When TOD is present, target and agent selection are condition‑specific. Default principle: smooth, titratable drips; avoid precipitous drops.

Compelling indications (need faster, deeper early control)

• Acute Aortic Dissection / Acute Aortic Syndrome
  • Goal: HR control first → SBP ≤120 mmHg within ~20 minutes.
  • Sequence: IV β‑blocker (esmolol/labetalol) → add vasodilator (nicardipine/clevidipine/nitroprusside) as needed.

Non‑compelling hypertensive emergencies (e.g., encephalopathy, AKI, acute HF without dissection)

• Hour 1: reduce SBP by ≤25%.
• Hours 2–6: if stable, to <160/100 mmHg.
• Next 24–48 h: cautiously toward 130–140 mmHg.

Agent pearls (select examples)

• Pulmonary edema: clevidipine, nitroglycerin, nitroprusside (avoid β‑blockers).
• ACS: esmolol/labetalol ± nicardipine; use nitrates with standard PDE‑5 precautions.
• Catecholamine excess (pheo, cocaine/amphetamine): nicardipine/clevidipine ± phentolamine; avoid β‑blocker monotherapy.

---

3) Stroke: Prioritize Perfusion — Precise Targets

Ischemic Stroke

• Thrombolysis candidate: <185/110 before alteplase/tenecteplase; then <180/105 for 24 h.
• No reperfusion therapy and BP <220/120: no acute BP lowering in first 48–72 h (Class 3: No Benefit). If ≥220/120 and no other compelling indication, a modest ~15% reduction in 24 h is reasonable.
• After successful EVT:
  • Do not lower SBP <140 in first 24–72 h (Class 3: Harm).
  • It’s reasonable to maintain ≤180/105 for 24 h post‑procedure.

Intracerebral Hemorrhage (ICH)

• Presenting SBP 150–220: immediately lower to 130 to <140 and maintain 7 days; stop antihypertensives if SBP <130.
• If SBP >220: do not drop <130 (harm signal); favor smooth, non‑labile lowering and avoid variability.

ED pearl: In both AIS and ICH, variability and over‑correction drive worse outcomes—prioritize steady titration over aggressive boluses.

---

4) Pregnancy & the Peripartum Window

Chronic HTN in pregnancy: Treat to <140/90 (shift from permissive control). First‑line maintenance: labetalol or extended‑release nifedipine.

Severe‑range BP (≥160/110): Medical emergency. Confirm in ≤15 min; treat within 30–60 min to <160/<110 using IV labetalol, IV hydralazine, or oral immediate‑release nifedipine (fastest to target in pregnancy).

Avoid (Class 3: Harm): atenolol, ACEi, ARB, direct renin inhibitors, nitroprusside, MRAs (spironolactone/eplerenone).

Postpartum: arrange BP check at 3–10 days; encourage HBPM; tailor titration.

ED pearl: Any pregnant or postpartum patient with headache, vision change, RUQ pain, or dyspnea gets preeclampsia workup + severe‑range treatment/OB consult.

---

5) Risk‑Based Treatment Thresholds (PREVENT™)

Risk assessment now uses PREVENT™ (replaces Pooled Cohort Equations for HTN decisions).

• Start/continue medications at ≥130/80 if 10‑yr PREVENT CVD risk ≥7.5% or if CVD, CKD, or diabetes are present.
• With risk <7.5%, start meds if ≥130/80 persists after 3–6 months of lifestyle therapy.

ED application: For severe HTN discharges, embed risk‑informed counseling and ensure primary care follow‑up to finalize long‑term targets.

---

6) Measurement & Disposition

Measurement matters:

• Use validated upper‑arm oscillometric devices with the right cuff size (see validated device lists).
• Avoid cuffless wearables (smartwatches, etc.) for diagnosis or management due to insufficient precision.

Disposition for Severe HTN (no TOD):

• Start/adjust simple once‑daily regimen; favor single‑pill combos when appropriate.
• Provide HBPM protocol (2 readings AM/PM × 7 days, discard day 1, average rest) and clear return precautions.
• Follow‑up within days (especially if stage 2, Black patients, CKD/diabetes, or pregnancy‑capable/postpartum).

---

7) Practical ED Algorithm

1. Confirm the number: correct cuff, position, repeat after rest; address pain/anxiety/volume.
2. Screen for TOD: neuro exam ± CT, chest pain/ECG/troponin, dyspnea/O2, urine, creatinine, fundi if visual sx, aortic “can’t‑miss” features → bedside POCUS as able.
3. Classify
   • Severe HTN (no TOD) → orals, HBPM, follow‑up.
   • Hypertensive emergency (TOD) → ICU, drips, target by condition.
4. Select agent(s)
   • Aortic dissection: esmolol→nicardipine/clevidipine; HR and SBP goals fast.
   • AIS/ICH: follow section‑specific targets above.
   • Pulmonary edema: vasodilators; avoid β‑blockers.
   • Pregnancy: labetalol / hydralazine / IR nifedipine; avoid fetal‑harm agents.
5. Reassess & avoid variability: titrate to steady targets; avoid large swings and overshoot.
6. Discharge plan (no TOD): Rx + HBPM + follow‑up; teach return precautions (neuro sx, chest pain, dyspnea, vision change, anuria).

---

Deep Review: Why These Changes?

Retiring “Urgency”

The term drove over‑treatment; data show iatrogenic hypoperfusion without benefit. Many patients experience spontaneous BP decline without intervention. The guideline codifies an outpatient‑first approach and flags harm from intermittent IV pushes in hospitalized, non‑cardiac patients with no TOD.

Condition‑Specific Targets

One size fits none in emergencies. Aortic dissection mortality tracks tightly with SBP → hence rapid β‑blockade and early SBP ≤120. For most other emergencies, gradual reduction preserves autoregulation and limits AKI/ischemia.

Stroke: Protect the Penumbra

Aggressive early lowering in AIS risks worsening perfusion, and trials show no benefit to routine early treatment <220/120 without reperfusion. Post‑EVT RCTs (ENCHANTED‑2 MT, OPTIMAL BP, BEST‑II) show harm or no benefit with intensive targets, so avoid <140. In ICH, the signal flips: 130–<140 with smooth control reduces hematoma expansion and improves outcomes; <130 can be harmful.

Pregnancy

Severe‑range hypertension is a time‑sensitive maternal safety issue—treat within 30–60 minutes. Atenolol, RAS blockers, nitroprusside, and MRAs carry fetal risk and are contraindicated. CHAP supports tighter <140/90 maintenance for chronic HTN.

Risk, Measurement, and Disposition

PREVENT™ lowers the risk threshold where meds are indicated (≥7.5% 10‑yr risk). Accurate diagnosis depends on validated devices and standardized technique; cuffless wearables aren’t ready for clinical decision‑making. For severe HTN without TOD, ED value is starting the long game—simple once‑daily or single‑pill combos, HBPM, and rapid follow‑up.

---

One‑Pager: Numbers to Remember

• Severe HTN (no TOD): >180/120 → no IV pushes, orals + follow‑up.
• Aortic dissection: β‑blocker first, SBP ≤120 in ≈20 min.
• AIS: <185/110 to give thrombolysis; then <180/105 ×24 h; avoid <140 after successful EVT (24–72 h).
• ICH: if SBP 150–220, target 130–<140 ×7 d; stop if <130.
• Pregnancy severe‑range: ≥160/110 → treat within 30–60 min to <160/<110 (labetalol/hydralazine/IR nifedipine). Chronic HTN goal <140/90.
• Stage 2 HTN: favor single‑pill 2‑drug start.
• Cuffless wearables: Do not use for diagnosis/management.

---

Jones DW et al. 2025 AHA/ACC/… Multisociety Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Circulation 2025.